title: Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo.
abstract: Tumor necrosis factor alpha (TNF alpha), a primary mediator of systemic responses to sepsis and infection, can be injurious to the organism when present in excessive quantities. Here we report that two types of naturally occurring soluble TNF receptors (sTNFR-I and sTNFR-II) circulate in human experimental endotoxemia and in critically ill patients and demonstrate that they neutralize TNF alpha-induced cytotoxicity and immunoreactivity in vitro. Utilizing immunoassays that discriminate between total sTNFR-I and sTNFR-I not bound to TNF alpha, we show that sTNFR-I-TNF alpha complexes may circulate even in the absence of detectable free TNF alpha. To investigate the therapeutic possibilities of sTNFR-I, recombinant protein was administered to nonhuman primates with lethal bacteremia and found to attenuate hemodynamic collapse and cytokine induction. We conclude that soluble receptors for TNF alpha are inducible in inflammation and circulate at levels sufficient to block the in vitro cytotoxicity associated with TNF alpha levels observed in nonlethal infection. Administration of sTNFR-I can prevent the adverse pathologic sequelae caused by the exaggerated TNF alpha production observed in lethal sepsis.
authors.affiliation: Laboratory of Surgical Metabolism, New York Hospital-Cornell University Medical Center, NY 10021.
authors.forename: K J
authors.initials: KJ
authors.lastname: Van Zee
authors.forename: T
authors.initials: T
authors.lastname: Kohno
authors.forename: E
authors.initials: E
authors.lastname: Fischer
authors.forename: C S
authors.initials: CS
authors.lastname: Rock
authors.forename: L L
authors.initials: LL
authors.lastname: Moldawer
authors.forename: S F
authors.initials: SF
authors.lastname: Lowry
mesh_terms: D000818:Animals; D002470:Cell Survival / Q000187:drug effects; D006801:Humans; D007249:Inflammation / Q000097:blood*; D008070:Lipopolysaccharides / Q000008:administration & dosage; D010215:Papio; D011956:Receptors, Cell Surface / Q000737:chemistry / Q000378:metabolism*; D018124:Receptors, Tumor Necrosis Factor; D011994:Recombinant Proteins / Q000627:therapeutic use; D018805:Sepsis / Q000628:therapy; D012995:Solubility; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors / Q000378:metabolism* / Q000633:toxicity
chemical_list: D008070:Lipopolysaccharides; D011956:Receptors, Cell Surface; D018124:Receptors, Tumor Necrosis Factor; D011994:Recombinant Proteins; D014409:Tumor Necrosis Factor-alpha